S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
NASDAQ:VRNA

Verona Pharma (VRNA) Stock Price, News & Analysis

$18.19
+0.97 (+5.63%)
(As of 03/1/2024 ET)
Today's Range
$17.24
$18.49
50-Day Range
$16.28
$20.47
52-Week Range
$11.83
$23.81
Volume
478,846 shs
Average Volume
467,918 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.60

Verona Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
79.2% Upside
$32.60 Price Target
Short Interest
Bearish
12.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.82mentions of Verona Pharma in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.02) to ($0.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.27 out of 5 stars

Medical Sector

789th out of 951 stocks

Pharmaceutical Preparations Industry

354th out of 430 stocks


VRNA stock logo

About Verona Pharma Stock (NASDAQ:VRNA)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Stock Price History

VRNA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Verona Pharma earnings preview: what to expect
When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?
Verona Pharma PLC ADR
Verona Pharma (VRNA) Scheduled to Post Earnings on Thursday
VRNA Mar 2024 15.000 put
VRNA Jun 2024 30.000 call
Verona Pharma: A Few Points From The Bull And Bear Case
Verona Pharma PLC ADR (VRNA)
Piper Sandler Reaffirms Their Buy Rating on Verona Pharma (VRNA)
Verona Pharma Secures Debt Facility Of Up To $400 Mln
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/29/2020
Today
3/02/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.60
High Stock Price Target
$35.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+79.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-68,700,000.00
Pretax Margin
-10,946.07%

Debt

Sales & Book Value

Annual Sales
$458,000.00
Book Value
$3.05 per share

Miscellaneous

Free Float
76,822,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
0.42
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives















VRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings
or view top-rated stocks.

What is Verona Pharma's stock price target for 2024?

3 Wall Street research analysts have issued 12 month price objectives for Verona Pharma's shares. Their VRNA share price targets range from $31.00 to $35.00. On average, they predict the company's share price to reach $32.60 in the next year. This suggests a possible upside of 79.2% from the stock's current price.
View analysts price targets for VRNA
or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2024?

Verona Pharma's stock was trading at $19.88 at the beginning of 2024. Since then, VRNA stock has decreased by 8.5% and is now trading at $18.19.
View the best growth stocks for 2024 here
.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VRNA earnings forecast
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its earnings results on Thursday, October, 29th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.18.

What ETF holds Verona Pharma's stock ?

ALPS Medical Breakthroughs ETF holds 60,171 shares of VRNA stock, representing 1.19% of its portfolio.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (4.84%), Jennison Associates LLC (1.98%), Eventide Asset Management LLC (1.72%), First Turn Management LLC (1.51%), Bellevue Group AG (1.05%) and Avidity Partners Management LP (0.98%). Insiders that own company stock include Anders Ullman, Claire Poll, David R Ebsworth, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Martin Edwards, Orbimed Advisors Llc and Patrick John Finn.
View institutional ownership trends
.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRNA) was last updated on 3/3/2024 by MarketBeat.com Staff